.
MergerLinks Header Logo

Announced

Completed

Sequoia Capital China led a $100m Series B funding round in Bota Bio.

Financials

Edit Data
Transaction Value£72m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

biotechnology

Minority

Acquisition

Biotechnology

Venture Capital

Cross Border

Private

Friendly

Completed

Private Equity

United States

Synopsis

Edit

Sequoia Capital China led a $100m Series B funding round in Bota Bio, a global industrial biotechnology company. The round was joined by Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners and 5Y Capital. The new funds will be used to expand the company's global operations and build out Bota Bio's lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of the company's product pipeline in consumer goods, food, nutrition, and pharmaceutical products. "Bota Bio is rapidly delivering bio-based and biologically produced products at scale to replace fossil-fuel-based, energy-intensive products and processes with biologically produced sustainable alternatives. The Bota Bio team has developed a leading integrated platform to bring innovative and efficient solutions to market for their partners. We are confident that Bota will keep enhancing their ability to accelerate the development of bio-based products, creating more value for consumers, while contributing to sustainability on a global scale," Neil Shen, Sequoia Capital China Founding and Managing Partner.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US